These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27050782)

  • 1. Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas.
    Daniele S; La Pietra V; Barresi E; Di Maro S; Da Pozzo E; Robello M; La Motta C; Cosconati S; Taliani S; Marinelli L; Novellino E; Martini C; Da Settimo F
    J Med Chem; 2016 May; 59(10):4526-38. PubMed ID: 27050782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells.
    Daniele S; Barresi E; Zappelli E; Marinelli L; Novellino E; Da Settimo F; Taliani S; Trincavelli ML; Martini C
    Oncotarget; 2016 Feb; 7(7):7866-84. PubMed ID: 26761214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma.
    Daniele S; Taliani S; Da Pozzo E; Giacomelli C; Costa B; Trincavelli ML; Rossi L; La Pietra V; Barresi E; Carotenuto A; Limatola A; Lamberti A; Marinelli L; Novellino E; Da Settimo F; Martini C
    Sci Rep; 2014 Apr; 4():4749. PubMed ID: 24756113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
    Elkamhawy A; Viswanath AN; Pae AN; Kim HY; Heo JC; Park WK; Lee CO; Yang H; Kim KH; Nam DH; Seol HJ; Cho H; Roh EJ
    Eur J Med Chem; 2015 Oct; 103():210-22. PubMed ID: 26355532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
    Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
    Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 1,3,4-thiadiazole derivatives as anti-glioblastoma agents targeting the AKT pathway.
    Szeliga M; Karpińska M; Rola R; Niewiadomy A
    Bioorg Chem; 2020 Dec; 105():104362. PubMed ID: 33074121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GQSAR modeling and combinatorial library generation of 4-phenylquinazoline-2-carboxamide derivatives as antiproliferative agents in human Glioblastoma tumors.
    Goswami D; Goyal S; Jamal S; Jain R; Wahi D; Grover A
    Comput Biol Chem; 2017 Aug; 69():147-152. PubMed ID: 28420545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Optimization of New 3,6-Disubstitutedindole Derivatives and Their Evaluation as Anticancer Agents Targeting the MDM2/MDMx Complex.
    Rezk MS; Abdel-Halim M; Keeton A; Franklin D; Bauer M; Boeckler FM; Engel M; Hartmann RW; Zhang Y; Piazza GA; Abadi AH
    Chem Pharm Bull (Tokyo); 2016; 64(1):34-41. PubMed ID: 26726742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
    Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
    Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting MDM2-p53 interaction in Glioblastoma: Transcriptomic analysis and Peptide-Based inhibition strategy.
    Han M; Kakar M; Li W; Iqbal I; Hu X; Liu Y; Tang Q; Sun L; Shakir Y; Liu T
    Bioorg Chem; 2024 Sep; 150():107620. PubMed ID: 38991490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antiglioma zwitterionic pronucleotides with an FdUMP framework.
    Szymanska-Michalak A; Wawrzyniak D; Framski G; Stawinski J; Barciszewski J; Kraszewski A
    Eur J Med Chem; 2018 Jan; 144():682-691. PubMed ID: 29289891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
    Hardcastle IR; Liu J; Valeur E; Watson A; Ahmed SU; Blackburn TJ; Bennaceur K; Clegg W; Drummond C; Endicott JA; Golding BT; Griffin RJ; Gruber J; Haggerty K; Harrington RW; Hutton C; Kemp S; Lu X; McDonnell JM; Newell DR; Noble ME; Payne SL; Revill CH; Riedinger C; Xu Q; Lunec J
    J Med Chem; 2011 Mar; 54(5):1233-43. PubMed ID: 21314128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.
    Golubovskaya VM; Palma NL; Zheng M; Ho B; Magis A; Ostrov D; Cance WG
    Anticancer Agents Med Chem; 2013 May; 13(4):532-45. PubMed ID: 22292771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.
    Guo Z; Zhuang C; Zhu L; Zhang Y; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Miao Z; Zhang W
    Eur J Med Chem; 2012 Oct; 56():10-6. PubMed ID: 22940704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship refinement and further assessment of 4-phenylquinazoline-2-carboxamide translocator protein ligands as antiproliferative agents in human glioblastoma tumors.
    Castellano S; Taliani S; Viviano M; Milite C; Da Pozzo E; Costa B; Barresi E; Bruno A; Cosconati S; Marinelli L; Greco G; Novellino E; Sbardella G; Da Settimo F; Martini C
    J Med Chem; 2014 Mar; 57(6):2413-28. PubMed ID: 24580635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.